Story
Juventus to Seek Shareholder Approval for €250 Million Capital Increase

Summary
The Italian soccer club is asking shareholders to back a new share issue to strengthen its finances after forecasting another annual loss, with controlling shareholder Exor committing immediate support.
Italian soccer club Juventus announced it will ask shareholders to approve a capital increase of up to €250 million ($283 million) as it braces for another loss in the current fiscal year.
Details of the Plan
In a statement, the club said it will seek authorization for its board to execute the share issue in one or more tranches by the end of 2026. The funds are intended to strengthen Juventus's equity base and support its sporting competitiveness.
The capital raise is also earmarked for potential upgrades to strategic real estate, including its stadium in Turin, and to improve overall financial sustainability. The move comes as the club navigates a challenging financial period.
Shareholder Support and Financial Health
AdExor, the holding company of the Agnelli family and Juventus's controlling shareholder, has pledged its support for the capital increase. The company, which owns approximately 65% of Juventus, will immediately inject €60 million into the Serie A club.
This capital injection follows a reported loss of €66 million for the fiscal year that ended June 30, an increase from the €58.1 million loss in the prior year. The club attributed its forecast for another annual loss to its failure to qualify for this season’s lucrative UEFA Champions League.
Context and Outlook
Juventus has not recorded an annual profit since the 2016-2017 fiscal year, and investors have injected approximately €1 billion into the club over the past seven years. Despite the current challenges, the club stated it anticipates a "progressive improvement" in its financial results over the following two years.
Read next
More on Stocks
Dyne Therapeutics Shares Rise on Positive 12-Month Data for DM1 Drug
The clinical-stage biotech company reported significant functional improvements in patients with myotonic dystrophy type 1 (DM1) in its Phase 1/2 ACHIEVE trial, boosting investor confidence.

Accelevation Prices IPO at $18 Per Share Ahead of Nasdaq Debut
Accelevation Holdings Corp. has priced its initial public offering of 30 million shares at $18.00 each, with the majority of shares being sold by existing stockholders. The company is set to begin trading on the Nasdaq under the ticker ACCV.

TSA to Remove Chairs from Airport ID Checkpoints, Drawing Union Criticism
The Transportation Security Administration will require its officers to stand while checking IDs at US airports, a move the agency says enhances security but a major union decries as a disregard for worker safety.

Robinhood to Introduce 24/7 Trading with Weekend Access for Select US Stocks
The online brokerage announced it will allow users to trade a selection of US stocks and ETFs around the clock on weekends, a first for the platform and part of a broader industry shift toward continuous market access.